

ModernGraham Valuation

Agilent Technologies
Inc



Company Name:

Company Ticker A

Date of Analysis

3/9/2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$24,759,898,745	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	3.39	Pass
3. Earnings Stability	Positive EPS for 10 years prior		Pass
4. Dividend Record	Dividend Payments for 10 years prior		Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end		
5. Earnings Growth		-24.07%	Fail
6. Moderate PEmg Ratio	PEmg < 20	39.75	Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	4.99	Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	3.39	Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.69	Pass
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Pass
5. Earnings Growth	EPSmg greater than 5 years ago Score		Pass

Suitability

Defensive	No
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$1.96
MG Growth Estimate	0.62%
MG Value	\$19.11
MG Value based on 3% Growth	\$28.45
MG Value based on 0% Growth	\$16.68
Market Implied Growth Rate	15.62%

MG Opinion

Current Price	\$77.98
% of Intrinsic Value	407.98%
Opinion	Overvalued
MG Grade	C


Stage 3: Information for Further Research





Net Current Asset Value (NCAV)	-\$0.63
Graham Number	\$31.39
PEmg	39.75
Current Ratio	3.39
PB Ratio	4.99
Current Dividend	\$0.60
Dividend Yield	0.76%
Number of Consecutive Years of Dividend Growth	3

Useful Links:

ModernGraham tagged articles	Morningstar
Google Finance	MSN Money
Yahoo Finance	Seeking Alpha
GuruFocus	SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$3.05	Next Fiscal Year Estimate	\$1.96
Oct2018	\$0.97	Oct2018	\$1.43
Oct2017	\$2.10	Oct2017	\$1.67
Oct2016	\$1.40	Oct2016	\$1.61
Oct2015	\$1.20	Oct2015	\$1.88
Oct2014	\$1.62	Oct2014	\$2.27
Oct2013	\$2.13	Oct2013	\$2.40
Oct2012	\$3.27	Oct2012	\$2.35
Oct2011	\$2.85	Oct2011	\$1.80
Oct2010	\$1.94	Oct2010	\$1.71
Oct2009	-\$0.09	Oct2009	\$1.83
Oct2008	\$1.87	Oct2008	\$2.68
Oct2007	\$1.57	Oct2007	\$2.46
Oct2006	\$7.50	Oct2006	\$2.10
Oct2005	\$0.65	Oct2005	-\$0.72
Oct2004	\$0.75	Oct2004	-\$1.19
Oct2003	-\$4.35	Oct2003	-\$1.65
Oct2002	-\$2.22	Balance Sheet Information 1/1/2019	
Oct2001	\$0.38	Total Current Assets	\$3,712,000,000
Oct2000	\$1.66	Total Current Liabilities	\$1,095,000,000
Oct1999	\$1.35	Long-Term Debt	\$1,798,000,000
		Total Assets	\$8,952,000,000
		Intangible Assets	\$3,699,000,000
		Total Liabilities	\$3,916,000,000
		Shares Outstanding (Diluted Average)	322,000,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

- Other ModernGraham posts about the company**
- [Agilent Technologies Inc Valuation – May 2018 \\$A](#)
 - [Agilent Technologies Inc Valuation – February 2017 \\$A](#)
 - [Agilent Technologies Inc Valuation – August 2016 \\$A](#)
 - [Agilent Technologies Inc Valuation – February 2016](#)
 - [Agilent Technologies Inc. Valuation – October 2015 Update \\$A](#)

- Other ModernGraham posts about related companies**
- [ResMed Inc Valuation – March 2019 #RMD](#)
 - [Cooper Companies Inc Valuation – March 2019 #COO](#)
 - [Edwards Lifesciences Corp Valuation – March 2019 \\$EW](#)
 - [Boston Scientific Corporation Valuation – March 2019 \\$BSX](#)
 - [Baxter International Inc Valuation – March 2019 \\$BAX](#)
 - [Centene Corp Valuation – March 2019 \\$CNC](#)
 - [Abbott Laboratories Valuation – February 2019 \\$ABT](#)
 - [Becton Dickinson and Co Valuation – February 2019 \\$BDX](#)
 - [IQVIA Holdings Inc Valuation – February 2019 \\$IQV](#)
 - [Thermo Fisher Scientific Inc Valuation – February 2019 \\$TMO](#)